Published 1 day ago • loading... • Updated 1 day ago

GLP-1 drugs tied to blood pressure risks in certain patients, study finds

A Northwestern University study presented over the weekend at ENDO 2026 analyzed health records from more than 42,000 adults, identifying a potential safety concern linking GLP-1 medications to complications related to low blood pressure.
After starting GLP-1s, patients experienced higher rates of dizziness and fainting, with hypotensive events rising from 8.7% to 10.2% within six months and persisting at 12 months, increasing to 14.3%.
Northwestern researcher Eimer observed patients with lightheadedness and fainting while on the drugs, stating, "Hypotension is the most dreaded potential side effect of treating hypertension and actually far more dangerous."
Eimer advised clinicians to monitor at-risk patients closely, stating, "Hey, think about the patients who are at risk and have a strategy to monitor and mitigate that risk." Secondary analysis showed weight loss alone did not explain the increased risk.
Despite the findings, Eimer remains a proponent of GLP-1s, noting the drugs help patients reduce blood pressure medications while advising, "Let's be careful in select patients because I think there's the potential to do harm.

Insights by Ground AI

12 Articles

ENDO: GLP-1 receptor agonists tied to higher hypotension risk in patients on BP meds

Among patients with preexisting hypertension taking antihypertensive medications, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with an increase in hypotensive-related events, according to a study presented at ENDO 2026, the annual meeting of the Endocrine Society, held from June 13 to 16 in Chicago.

1 day ago

Read Full Article